TS
TEVA icon

Triglav Skladi’s Teva Pharmaceuticals TEVA Stock Holding History

Triglav Skladi’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$445K Hold
13,121
– – 0.02% 164
2026
Q1 		$395K Buy
13,121
+8,121
+162% +$261K 0.03% 151
2025
Q4 		$156K Buy
+5,000
New +$123K 0.01% 169

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Triglav Skladi's TEVA Position: Q2 2026 in Review

Triglav Skladi held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 13,121 shares worth $445K. The position accounts for 0.02% of the portfolio, ranked #164.

Triglav Skladi first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Triglav Skladi held 13,121 shares of Teva Pharmaceuticals worth $445K as of Q2 2026.
  • Triglav Skladi left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up 0.02% of Triglav Skladi's portfolio in Q2 2026, its #164 holding.
  • Triglav Skladi first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Triglav Skladi's 13F filing for Q2 2026, filed 11 Aug 2026.